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ABSTRACT
Introduction: The ICON1 study (a study to Improve
Cardiovascular Outcomes in high-risk older patieNts
with acute coronary syndrome) is a prospective
observational study of older patients (≥75 years old)
with non-ST-elevation acute coronary syndrome
managed by contemporary treatment (pharmacological
and invasive). The aim of the study was to determine
the predictors of poor cardiovascular outcomes in this
age group and to generate a risk prediction tool.
Methods and analysis: Participants are recruited
from 2 tertiary hospitals in the UK. Baseline evaluation
includes frailty, comorbidity, cognition and quality-of-
life measures, inflammatory status assessed by a
biomarker panel, including microRNAs, senescence
assessed by telomere length and telomerase activity,
cardiovascular status assessed by arterial stiffness,
endothelial function, carotid intima media thickness
and left ventricular systolic and diastolic function, and
coronary plaque assessed by virtual histology
intravascular ultrasound and optical coherence
tomography. The patients are followed-up at 30 days
and at 1 year for primary outcome measures of death,
myocardial infarction, stroke, unplanned
revascularisation, bleeding and rehospitalisation.
Ethics and dissemination: The study has been
approved by the regional ethics committee (REC
12/NE/016). Findings of the study will be presented in
scientific sessions and will be published in peer-
reviewed journals.
Trial registration number: NCT01933581: Pre-
results.
INTRODUCTION
In the general population, ischaemic heart
disease (IHD) is the leading cause of death
worldwide.1 Mortality due to IHD increases
steeply among those aged >70 years.2 In
2010, in the UK, more than twice as many
individuals >75 years of age (n=55 028) died
from IHD, compared to younger individuals
<75 years (n=25 540).3 According to the
Myocardial Ischaemia National Audit Project
Database annual public report 2012–2013,
there were 80 974 admissions with a final
diagnosis of myocardial infarction (MI). Of
these, 60% had non-ST-elevation myocardial
infarction (NSTEMI). Of the patients with
NSTEMI, 59% were >70 years of age (26%
were aged 70–79 years, 26% were aged 80–
89 years and 7% were aged ≥90 years).4
Strengths and limitations of this study
▪ Older patients with non-ST-elevation acute cor-
onary syndrome represent a high-risk population,
who remain understudied in contemporary car-
diovascular research.
▪ This prospective cohort study is designed and
powered to identify risk factors for adverse out-
comes, at 30 days and 1 year, in patients aged
≥75 years undergoing invasive management of
non-ST-elevation acute coronary syndrome.
▪ This study will evaluate the role of frailty, using a
well-defined frailty index, and invasive imaging
modalities (including optical coherence tomog-
raphy and virtual histology intravascular ultra-
sound) as determinants of clinical outcome and
also evaluate the quality of life in this age group.
▪ Limitations include (1) the non-randomised char-
acter of this study, which is not able to derive
definitive insights regarding the causality of
factors associated with clinical outcomes, and
(2) that intracoronary imaging will be performed
in only a subset of patients recruited, owing to
anatomical contraindications and patient wishes.
▪ The results of this study will enable improved
risk stratification for older patients presenting
with non-ST-elevation acute coronary syndrome
and will have implications for the design of
future clinical trials in this high-risk population.
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Mortality benefit from advances in the management of
acute coronary syndrome (ACS) has largely been rea-
lised in patients aged <65 years.2 There has been an
increase in IHD burden in older patients, who are at
risk of poorer outcomes due to frailty and comorbidity.5
Until recent years, there has persisted a paucity of evi-
dence from clinical trials and studies to inform the man-
agement of ACS in older patients. More than half of all
randomised controlled trials for ACS failed to enrol parti-
cipants >75 years of age and, even in those that did, only
9% were >75 years of age.6 Notable studies, recruiting
patients >75 years of age, have been reported in recent
years, in the context of invasive and non-invasive manage-
ment of ST-elevation MI and non-ST-elevation ACS.7–10
Evidence-based recommendations from trials do not
account for age-related differences in physiology, disease
and comorbidities, which may alter the risk–benefit
profile of cardiovascular treatments and interventions.
The age mismatch between trial and community popula-
tions begins at 75 years and widens with age.11
Furthermore, older people who are included in trials
have lower than expected rates of traditional cardiovascu-
lar risk factors, fewer comorbidities and better renal func-
tion than the community population.12 Risks and
benefits derived from trials cannot always be extrapolated
to older patients in daily clinical practice due to the dif-
ferences between the patient groups and their baseline
characteristics.13
In the ageing population, there is increasing evidence
for the association of cardiovascular disease (CVD) and
frailty.14 Depending on the frailty scale used and the
population studied, almost half of the patients with CVD
can be identified as frail.15 There is an increased risk of
mortality and major adverse cardiovascular events in
frail patients with CVD, especially those undergoing
invasive procedures or suffering from coronary artery
disease and heart failure.15 In patients aged >75 years,
frailty was strongly and independently associated with
in-hospital mortality (OR 4.6; 95% CI 1.3 to 16.8) and
1 month mortality (OR 4.7; 95% CI 1.7 to 13.0).16 At
1 year, there was a significant increase in mortality
among frail patients compared with non-frail patients
(HR 4.3, 95% CI 2.4 to 7.8).17 Similarly, in >65-year-old
patients, frailty was associated with increased long-term
mortality and MI among patients undergoing percutan-
eous coronary intervention (PCI).18
No studies have been performed in older patients
undergoing an invasive treatment strategy to evaluate
predictors of poor outcomes or to develop strategies to
improve outcomes following ACS. The ACS and PCI risk
models that are currently available were mainly derived
from patients <65 years of age and, hence, cannot be
applied to the increasing proportion of older patients
(aged >75 years) with ACS managed by contemporary
treatment.19 The goal of Improve Cardiovascular
Outcomes in high-risk older patieNts with acute coron-
ary syndrome (ICON1) study is to determine the predic-
tors of adverse outcomes (death, MI, stroke, repeat,
unplanned revascularisation, bleeding and rehospitalisa-
tion for any reason) at 1 month and at 1 year following
invasive management of non-ST-elevation acute coronary
syndrome (NSTEACS) in older patients and to develop
an integrated risk score to predict adverse outcomes at
1 year that will inform clinical decision-making. In add-
ition, the impact of contemporary NSTEACS manage-
ment on the quality of life will be assessed.
HYPOTHESIS
Frailty and comorbid status in older patients are asso-
ciated with worse outcomes following invasive treatment
for NSTEACS.
TRIAL DESIGN
The study has been designed as a multicentre, prospect-
ive, observational study of patients aged ≥75 years under-
going invasive management (coronary angiography with
a view to revascularisation) for NSTEACS.
METHODS
Study setting
This ongoing, multicentre, observational study is being
conducted in two tertiary cardiac care hospitals in the
North-East of England. The Freeman Hospital, in
Newcastle upon Tyne, is a tertiary cardiac centre with a
catchment population of 2 million. Approximately 3000
PCI procedures are performed each year. The James
Cook University Hospital, in Middlesbrough, performs
∼1750 PCI procedures every year. The study participants
are recruited from patients referred to these hospitals
from the neighbouring district general hospitals for inva-
sive treatment of NSTEACS. Patients are diagnosed on
the basis of clinical symptoms, electrocardiography cri-
teria and high-sensitivity troponin testing, in line with
guidelines20 21 transferred the day before or on the day
of procedure to the tertiary hospitals. Prospective
ICON1 patients are identified from an electronic refer-
ral system and, on arrival to the tertiary hospitals, are
approached for recruitment into the study. The research
team explains the study to the patients and a patient
information sheet is provided. If a patient agrees to par-
ticipate in the study, a written informed consent is
obtained. All patients screened for the study are entered
in a screening log, with details regarding the patients
consented, declined and consented but not recruited
(due to alternative diagnosis following coronary angiog-
raphy). The inclusion and exclusion criteria are shown
in box 1. Recruitment to the study started in October
2012 with the 1-year follow-up is projected to reach com-
pletion in December 2016.
Treatment protocol
During the course of the study, the patients were treated
according to contemporary evidenced-based guidelines,
as directed by an interventional cardiologist, at the time
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of study enrolment.20 21 According to standard practice,
the patients are revascularised by PCI or coronary artery
bypass graft surgery. The patients may also be managed
medically, if deemed not appropriate for either of the
revascularisation strategies at the discretion of the oper-
ating cardiologist.
Data collection
Data are collected on standardised case report forms by
members of the research team. The data collected
include demographics, baseline characteristics, and
details of coronary angiography and/or PCI.
Periprocedural complications and in-hospital complica-
tions are recorded. Further data are collected on the
cardiovascular status, Canadian Cardiovascular Society
(CCS) angina grade, New York Heart Association
(NYHA) dyspnoea grade, frailty category, functional
health status, quality of life and cognitive status. These
are listed in box 2. The assessments and techniques
used for the above data collection are discussed in the
following sections. The study flow chart is displayed in
figure 1. All questionnaires were administered verbally,
in person and by a trained, clinical researcher.
Appropriate training was provided to researchers, ensur-
ing that these scripted questionnaires were performed,
and results recorded, in an unbiased fashion.
Frailty and comorbidity assessments
Frailty is assessed by Fried Frailty Index, derived from
Cardiovascular Health Study22 and Rockwood Frailty
Index, derived from Canadian Study of Health and
Aging.23 The Fried Frailty Index is based on assessing
five criteria, comprising subjective answers provided by
the patient (regarding weight loss, physical energy, phys-
ical activity) and objective assessment (hand grip
strength). A score of 0 is categorised as robust, 1 or 2 as
intermediate or pre-frail and 3 or more as frail (see
online supplementary appendix 1). The Rockwood
Frailty Index is, based on the assessment by the research-
ers, grouped into categories 1–7, from very fit to severely
frail, depending on functional status and independ-
ence/dependence on others for activities of daily living
(see online supplementary appendix 2).
In addition, the Charlson Comorbidity Index,24 a
method of predicting mortality based on a weighted
index of the number and seriousness of comorbid con-
ditions, is evaluated for each patient. The Charlson
Box 2 ICON1 study assessments
Biomarkers:
▸ High-sensitive C reactive protein
▸ Vitamin D
▸ Myeloperoxidase
▸ Asymmetric dimethyl arginine
▸ Eicosapentaenoic acid
▸ Docosahexaenoic acid
▸ Soluble p selectin
▸ Cluster differentiation 40
▸ Lipoprotein-associated phospholipase A2
▸ Interleukin-6
▸ Tumour necrosis factor-α
▸ N-terminal prohormone brain natriuretic peptide
▸ MicroRNAs (miR-21-5p, miR-126-5p, miR-132-3p,
miR-133a-3p, miR-142-3p, miR-150-5p, miR-208-3p,
miR-223-3p and miR-320a)
▸ Peripheral blood mononuclear cells
– Telomere length
– Telomerase activity
Intracoronary imaging:
▸ Virtual histology intravascular ultrasound
▸ Optical coherence tomography
Cardiovascular status:
▸ Arterial stiffness
▸ Peripheral arterial tonometry
▸ Carotid intima media thickness
▸ Transthoracic echocardiogram
Cardiac symptoms:
▸ New York Heart Association dyspnoea
▸ Canadian Cardiovascular Society angina
Frailty assessment:
▸ Fried Frailty Index
▸ Rockwood Frailty Index
Quality of life (Qol):
▸ SF-36, EuroQol-5D (EQ-5D)
Cognitive status:
▸ Montreal Cognitive Assessment (permission to use MoCA
test obtained from MoCA team (on behalf of Dr
Ziad Nasreddine))
Comorbidity:
▸ Charlson Comorbidity Index
Box 1 Inclusion and exclusion criteria
Inclusion criteria:
▸ ≥75 years old
▸ Non-ST-elevation acute coronary syndrome
▸ Planned for coronary angiogram (CA) or percutaneous coron-
ary intervention
Exclusion criteria:
▸ Cardiogenic shock
▸ Primary arrhythmias
▸ Significant valvular heart disease
▸ Malignancy with life expectancy <1 year
Active infection:
– Urinary tract infection
– Pneumonia
– Sepsis
Alternative diagnosis after CA (excluded after consent):
– Pulmonary embolism
– Takotsubo cardiomyopathy
– Myocarditis
– Coronary vasospasm
Unable to consent:
– Known dementia
– Language barrier
– Visual impairment
– Lack of capacity
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Comorbidity Index has been demonstrated to be an
appropriate indicator of in-hospital and 1-year outcomes
in the setting of ACS.25
Functional status and quality-of-life measures
The Short Form-36 Standard (SF-36 Standard) health
survey is completed by each patient prior to discharge
from the hospital and at 1-year follow-up to assess func-
tional health and quality of life. The responses will be
used to obtain physical component summary score and
mental component summary score.26 In addition, the
EQ-5D-3L questionnaire is used to assess the health
outcome of each patient at discharge and 1-year
follow-up.27 28
Cognitive status assessment
Atherosclerosis is associated with increased risk of cogni-
tive impairment in older patients.29 To assess the cogni-
tive status of patients during admission, the Montreal
Cognitive Assessment (MoCA)30 test is used. The MoCA
has been shown to have high sensitivity in screening
patients with known CVD for mild cognitive impairment,
even in a non-memory clinic setting.31 This test is
repeated at 1-year follow-up.
Biomarker sampling
Blood samples are collected at the time of coronary
angiography and/or PCI for biomarker analysis. Serum
for biomarkers is stored for analysis in batches.
Peripheral blood mononuclear cells are separated by
centrifugation techniques for storage at −80°C for ana-
lysis of telomeres and telomerase activity. High-sensitivity
C reactive protein (hsCRP), parathyroid hormone and
total vitamin D are analysed. Full blood count, renal
function, blood glucose, cholesterol and high-sensitivity
cardiac troponin T levels are measured in patients as
part of our routine care.
Inflammation plays a central role in acute thrombotic
complications of unstable atherosclerotic coronary
plaque. Increased levels of markers of inflammation
predict CV outcomes following ACS. Inflammatory
markers including myeloperoxidase,32 hsCRP33 and
soluble CD40 ligand34 have been associated with ACS and
have been shown to predict the outcome. The patients
with ACS have decreased levels of anti-inflammatory ω-3
fatty acids (eicosapentaenoic acid and docosahexaenoic
acid).35 Increased lipoprotein-associated phospholipase
A2 activity has been associated with increased cardiovas-
cular event rates.36 37 An elevated level of asymmetric
dimethyl arginine is a strong and independent predictor
of adverse outcomes following ACS.38 Interleukin-6
(IL-6) levels in the serum were increased in patients with
ACS.39 IL-6 expressed in atherosclerotic plaques may
increase plaque instability.40 Elevated IL-6 was a predictor
of 6-month and 12-month mortality in patients with
unstable coronary artery disease.41 Tumour necrosis
factor-α (TNF-α) is a proinflammatory cytokine asso-
ciated with myocardial dysfunction and remodelling fol-
lowing ACS.42 In patients with recent MI, increased levels
of TNF-α were associated with adverse cardiovascular out-
comes (recurrent MI and cardiac death).43 Vitamin D
deficiency has been associated with elevated CAD burden
and worse cardiovascular outcomes.44 These biomarkers
will be analysed in this group of ≥75-year-old patients to
enable the determination of predictors of adverse CVout-
comes at 1 year. Telomere shortening has been associated
with ageing and senescence, and shorter leucocyte telo-
meres are associated with increased cardiovascular risk
and mortality.45 Shorter leucocyte telomere length pre-
dicted high-risk plaque morphology on virtual histology
intravascular ultrasound (VH-IVUS).46 Whether shorter
telomere length is a predictor of adverse events among
older patients undergoing PCI is not known and will be
evaluated in this study.
MicroRNA analysis
MicroRNAs (miRNAs) are small non-coding RNAs that
post-transcriptionally inhibit gene expression.47 In the
Figure 1 ICON1 study flow
chart. CCS, Canadian
Cardiovascular Society; ICON1,
Improve Cardiovascular
Outcomes in high-risk older
patieNts with acute coronary
syndrome; MoCA, Montreal
Cognitive Assessment; NSTEMI,
non-ST-elevation acute coronary
syndrome; NYHA, New York
Heart Association; OCT, optical
coherence tomography; PCI,
percutaneous coronary
intervention; UA, unstable angina;
VH-IVUS, virtual histology—
intravascular ultrasound.
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past few years, miRNAs have emerged as key tools for the
understanding of IHD pathophysiology, with great poten-
tial to be used as new biomarkers and therapeutic targets.
miRNAs seem to possess ideal characteristics to be used
as disease biomarkers, as they are detectable in biofluids
in a reproducible and stable fashion, even after years of
sample storage and freeze–thaw cycles.48 In the blood,
circulating miRNAs are found mainly within extracellular
vesicles, such as exosomes, microvesicles and apoptotic
bodies,49 and, to a lesser extent, associated with
HDL-cholesterol particles50 51 or Argonaute-2 protein.52
Several studies have demonstrated elevated or decreased
levels of specific circulating miRNAs in patients with
ACS.53–56 However, few have addressed their prognostic
value with regards to major cardiovascular events57 or
death,58 especially among older cohorts of patients
presenting with NSTEACS.
The levels of nine circulating miRNAs, known to be
differentially expressed in patients with ACS (miR-21-5p,
miR-126-5p, miR-132-3p, miR-133a-3p, miR-142-3p,
miR-150-5p, miR-208-3p, miR-223-3p and miR-320a), will
be quantified by reverse transcription quantitative PCR,
in serum and circulating microvesicles (isolated from an
additional 200 μL of serum) and correlated with clinical
variables with a view to assess their value as a prognostic
biomarker in older patients with NSTEACS.
Invasive coronary artery imaging
Postmortem studies have identified that vulnerable
plaques, with specific morphological characteristics, are
implicated in the pathophysiology of ACS. These
plaques, which are prone to erosion and rupture, have
inflamed fibrous caps, rich in macrophages, overlying a
lipid pool.59 Burke et al60 examined the hearts of 113
men who had died suddenly and found that 95% of rup-
tured plaques had fibrous caps <65 µm thick (mean
thickness 23±19 µm) with an infiltrate of macrophages.
ICON1 aims to identify whether the increased mortality
in the older population with ACS is due to an increased
prevalence of these vulnerable thin-capped fibroather-
oma (TCFAs). Following diagnostic coronary angiog-
raphy, the patients undergo VH-IVUS imaging and
optical coherence tomography (OCT) imaging in all
three coronary arteries prior to PCI, where feasible and
not contraindicated, and VH-IVUS imaging post-PCI in
the culprit vessel at the discretion of the operating
cardiologist.
Virtual histology intravascular ultrasound
The greyscale IVUS image uses only the amplitude of
the reflected ultrasound wave. VH-IVUS uses spectral
analysis of the frequency and power of the reflected
wave to generate a more accurate reflection of the tissue
subtypes present within the vessel wall.61 This can then
be used to differentiate plaque components (fibrous,
fibro-fatty, dense calcium and necrotic core) and identify
high-risk vulnerable plaques. Although VH-IVUS lacks
the resolution to identify the thin fibrous cap of the
TCFA, it is well placed to accurately identify the necrotic
core of these plaques.61 A 20 MHz, phased-array Eagle
Eye Platinum catheter is mounted on an R-100 pullback
device and connected to either an integrated S5i system
or a mobile S5 tower. Image acquisition is performed at
a pullback speed of 0.5 mm/s and is ECG-gated to
ensure one frame is acquired per cardiac cycle. The
maximum length of all three coronary arteries is
imaged, where feasible and not contraindicated.62 The
data are anonymised and transferred to DVD for off-line
data analysis. The operator is blinded to these data.
VH-IVUS data analysis is performed using the Medis
QIvus software v2.0 (Leiden, the Netherlands). Contours
are drawn manually around the external elastic membrane
and lumen of the vessel for each greyscale IVUS frame,
excluding any ring-down artefact or previously stented seg-
ments. The software then calculates several parameters
such as minimum lumen area and diameter, per cent sten-
osis, and absolute volume and percentage of each plaque
component. The image reader can also calculate the
remodelling index63 and classify the lesion type from these
data. Lesion classification in ICON1 is based on previously
published recommendations for tissue characterisation by
radiofrequency data analysis (figure 2).62
Optical coherence tomography
OCT generates an image analogous to IVUS using a low
coherence, near-infrared (wavelength 1.3 µm) light
source, instead of sound.64 A bloodless field inside the
coronary artery is vital, as red blood cells strongly back-
scatter the near-infrared light. This is obtained by using
a flush of contrast during image acquisition. OCT has a
greater resolution than IVUS (20–40 vs 100–200 µm)
and is thus able to delineate the thin fibrous cap present
in a TCFA. However, its poorer penetration (1–2.5 mm)
can limit its capacity to identify deep lipid pools and
quantify plaque volume.65 66
OCT images are obtained using a Dragonfly catheter
(St Jude Medical, Minnesota, USA) connected to the
Ilumien PCI Optimization System. Just before image
acquisition, a short flush of iso-osmolar contrast is admi-
nistered to ensure that the guide catheter is well
engaged with the coronary artery and the catheter is
clear of blood. The system is calibrated and OCT pull-
back is initiated with a further flush of iso-osmolar con-
trast (10 mL in the right coronary artery and 15 mL in
the left coronary artery). OCT images are obtained in
54 mm segments at a pullback rate of 20 mm/s in all
three coronary arteries, where feasible. Data are trans-
ferred anonymously to a DVD for off-line analysis; the
operator is blinded to these data during the procedure.
OCT data are analysed using the Medis QIvus software.
Contours are drawn around the lumen to generate data
on the minimum lumen area and diameter. The whole
vessel is then analysed to identify plaque subtypes. An ath-
erosclerotic lesion is seen on OCT as a mass lesion within
the arterial wall, with focal intimal thickening or loss of
the normal vessel architecture.67 Fibrous plaque is
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homogenous and highly backscattering, calcified plaques
are signal-poor areas with sharply delineated borders and
lipid pools are signal-poor regions with poorly defined
borders and a fast OCT signal drop-off.67 Using side
branches and areas of calcification as landmarks, it is pos-
sible to compare the accuracy of lesion subtypes identi-
fied by VH-IVUS and OCT.
NON-INVASIVE ASSESSMENT OF CARDIOVASCULAR
STATUS
Arterial stiffness
Arterial stiffness is now increasingly recognised as a surro-
gate end point for the assessment of CVD status.68 It can
lead to angina in the presence of even minor coronary
artery disease and to the development of diastolic dysfunc-
tion, the commonest form of heart failure in the elderly.69
Arterial stiffness is determined by carotid-femoral pulse-
wave velocity (PWV), which is a simple, non-invasive,
robust and reproducible investigation method that can be
performed at the bedside.68 In older patients, arterial stiff-
ness assessed by increased PWV is associated with poor car-
diovascular outcomes.70 In the ICON1 study,
carotid-femoral PWV is assessed by the Vicorder device
(Skidmore Medical Limited, Bristol, UK). In addition, bra-
chiofemoral PWV, pulse-wave analysis (includes pulse pres-
sure, augmentation pressure and augmentation index)
and ankle brachial pressure index are also assessed.
Endothelial function
Endothelial dysfunction is considered one of the earliest
markers of atherosclerosis,71 contributing to lesion devel-
opment and its later clinical manifestations.72 73 It is asso-
ciated with increased risk of cardiovascular events and has
been proposed as a marker of poor CV outcomes.74–76
Peripheral arterial tonometry (PAT) by finger plethysmo-
graphy (EndoPAT; Itamar Medical, Caesarea, Israel) is a
novel method of measuring the peripheral vasodilator
response.77 78 Hyperaemic response measured by PAT
signal amplitude gives a measure of nitric oxide-mediated
endothelial function.79 80 In patients with low-risk findings
during stress testing and/or the absence of new obstructive
lesions on angiography, lower natural logarithmic-scaled
reactive hyperaemia index (<0.40) is associated with
increased cardiovascular death over 6 years.81 In the
ICON1 study, endothelial function is measured by
EndoPAT. PAT signals are recorded from the index fingers
with pneumatic probes at baseline, during cuff occlusion
and during hyperaemia. A measure of endothelial function
is calculated from the ratio of PAT signal amplitude at base-
line and postocclusion. Reactive hyperaemia index data
from the study will be used in the prediction of adverse CV
outcomes and will be incorporated in the risk model.
Carotid intima media thickness
Carotid intima media thickness (CIMT) is a significant
predictor of incident adverse cardiovascular events.82 83
Figure 2 Decision tree for lesion classification on VH-IVUS, virtual histology—intravascular ultrasound (VH-IVUS) with image
examples. Adapted from García-García et al.62
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Increased CIMT was associated with severity of coronary
atherosclerosis in ACS.84 CIMT and its association with
predicting CV events in older patients with NSTEACS
are not known. In a meta-analysis, addition of CIMT to
Framingham risk score in general population did not
improve 10-year prediction of first MI or stroke.85
However, CIMT and arterial stiffness together increase
the cardiovascular risk in patients with known vascular
disease or cardiovascular risk factors.86 In the ICON1
study, CIMT is assessed using a Vivid I GE machine, with
a vascular probe. CIMT measurement is obtained via
semiautomated software, which uses an edge detection
technique. CIMT values will be analysed for the predic-
tion of adverse outcomes and will be incorporated in
the risk model.
Transthoracic echocardiogram
In hospitalised elderly patients with known CVD, left
ventricular diastolic dysfunction was similar in preva-
lence to systolic dysfunction and was associated with
similar cardiovascular and all-cause mortality.87
Transthoracic echocardiography will be performed using
a Vivid I GE echo machine, according to the British
Society of Echocardiography guidelines, to assess systolic
function, diastolic function and valvular heart disease.88
Systolic and diastolic function will be analysed for the
prediction of adverse CV outcomes.
Follow-up
One-month outcomes are recorded using general practi-
tioner summary documents, obtained from the patients’
general practitioner. The patients are followed-up in a
study outpatient clinic at 1 year. During this follow-up visit,
repeat blood samples are collected for biomarker analysis.
In addition, NYHA class, CCS angina class, SF-36, EQ-5D
and MoCA assessments are completed. Frailty status is reas-
sessed using Fried and Rockwood Frailty Criteria.
Primary outcome measures
The primary outcome measure is a composite of death,
MI, stroke, repeat, unplanned revascularisation and BARC
(Bleeding Academic Research Consortium)-defined
bleeding (type 2 or greater) at 1 year (see online supple-
mentary appendices 3 and 4).89 90 We also intend to
analyse 1-year mortality as an independent outcome
measure. All-cause hospitalisation comprises a secondary
outcome measure.
Sample size
For the primary outcome, Hsieh and Lavori’s91 method
was used to calculate the power for testing the association
of the risk score with adverse outcomes, based on 300 par-
ticipants with a type I error rate of 0.05. From the national-
level registry data, the 1-year mortality rate for NSTEMI in
all patients undergoing invasive strategy is ∼2–5%.92
Estimates of the SD and HR of the risk score are unknown.
An assumption was made on the HRs being an increment
of 1 SD of the risk score (see figure 3).
STATISTICAL METHODS
Risk factor selection
Cox proportional hazards regression analysis will be per-
formed to estimate HRs of the risk factors and associated
p values for the primary outcome. Multiple logistic
regression analysis will be performed to estimate ORs of
the risk factors and associated p values for the secondary
outcome. The bootstrap method will be used to avoid
overfitting the data. One thousand bootstrapping will be
performed. For each bootstrapping, we will sample with
replacement 300 patients from the original 300 patients.
Backward selection with a p value of <0.05 for statistical
significance will be used to remove variables in each
sample. Variables selected ≥800 times (80%) in the
overall sample will be included in the final model. All
missing values will be reported, and appropriate statis-
tical methods will be used to handle missing values.
Risk score construction
To construct the risk score, risk factors identified
through the multivariable model will be assigned a
weight. Weights are the estimated regression coefficients
from the Cox proportional hazards regression or logistic
regression model. The risk score is thus the weighted
average of the identified risk factors. Another Cox pro-
portional hazards regression or logistic regression model
will be applied to detect the association of the proposed
risk score to the outcomes.
Risk score evaluation
Harrell’s C-index will be used to assess the discriminatory
capacity of the integrated risk score for primary and sec-
ondary outcomes. The Jackknife method will be used to
estimate the SE of the estimated Harrell’s C-index93 or
area under the curve. The difference between model-
predicted and observed event rates (goodness-of-fit) will
be evaluated using the Hosmer-Lemeshow test (p value
of >0.10 will be considered to indicate the lack of
Figure 3 Study power. A plot of power versus hazard ratios
for the sample size of 300 patients and 1-year mortality rates.
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deviation between the model-predicted and observed
event rates). Reclassification calibration measures (eg,
net reclassification improvement and integrated discrim-
ination improvement) will be used to evaluate the
improvement of new predictors (relative to existing pre-
dictors) on the agreement between observed and pre-
dicted outcomes.94 A cross-validation technique will be
used to assess how the results of statistical analysis gener-
alise to an independent data set.95 Finally, a prediction
nomogram96 will be developed to facilitate calculating
the risk scores and the corresponding survival probability
at 1 year.
CONCLUSION
The ICON1 study will identify predictors of poor cardiovas-
cular outcomes among older patients (aged ≥75 years)
presenting with NSTEACS managed by contemporary
pharmacotherapy and invasive revascularisation strategy.
Based on clinical characteristics, frailty status, comorbid-
ities and cardiovascular status, an integrated risk stratifica-
tion tool to help decision-making in the management of
older patients will be developed. The variables that we
hypothesise may be relevant to such a model would be
either (1) routinely collected in clinical practice as part of
current evidence-based practice or (2) should not be
unduly burdensome to collect during routine clinical
assessment.
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